Plain-English translation of NCT03300492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether expanded natural killer cells—special immune cells that fight cancer—can help prevent acute myeloid leukemia and myelodysplastic syndromes from coming back after stem cell transplant. You would receive the treatment from a partially matched family member donor. The study wants to make sure this new approach is safe and actually works.
Stem cell transplants from partially matched donors are an important option for blood cancer patients, but relapse remains a serious problem. This medication is designed to boost your immune system's ability to destroy any remaining cancer cells and prevent the disease from returning.
You likely qualify if…
You likely don't qualify if…
You would undergo a stem cell transplant as planned, then receive infusions of specially grown immune cells on days 10, 15, and 20 after your transplant. The doses would gradually increase over these three infusions. The study team will monitor you closely to watch for side effects and measure how well the immune cells work to control your cancer.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Switzerland